glp-1 medullary thyroid cancer Mixed and Papillary Carcinoma in a Patient on Tirzepatide GLP-1 warning in humans, not
Description
A systematic review
Both medications treat obesity and many related metabolic conditions, Isaacs said
They can yield 15%20% weight reductions in adults, previously only possible after bariatric surgery
[DOI] [PubMed] [Google Scholar] 62.Krajewski P.K., Zotowska A., Szepietowski J.C
Tirzepatide is one of the most popular GLP-1 agonists
A meta-analysis of GLP-1RA CVOT showed that treatment with GLP-1RA reduced the risk of developing a composite kidney outcome including new-onset MA by 21% compared to placebo (HR 0.79, 95% CI 0.73-0.87), with only ELIXA and EXSCEL not achieving significant benefit [11]
